Absolute Antibody

History of Innovation

2012
Absolute Antibody is founded with a vision to make recombinant antibody technology accessible to all.

2013
We introduce our HEXpress™ antibody expression platform for recombinant antibody production.

We develop our Fc Silent™ technology to produce antibodies without Fc receptor binding.

2014
We develop the AbFab2™ antibody format, a recombinant fragment with improved stability.

2015
We are recognized in a *Nature* article on the need to standardize research antibodies.

2016
We hit our 1,000th antibody production run.

The first peer-reviewed article citing an Absolute Antibody product is published.

2017
We start sequencing hybridomas using our high-throughput NGS approach.

2018
We merge with the Boston-based reagent company Kerafast and open a North American office.

We co-author an article in *mAbs* showing that 30% of monoclonal antibodies are not monospecific.

We hit 1,000 unique antibody clones in our reagents catalog, for a total of 4,000 engineered formats.

We develop our first custom high-throughput purification robot to increase production capacity.

Our antibody manufacturing facility in Northeast England expands and is ISO certified.

2019
We open a field office in Amsterdam dedicated to catalog management and innovation.

We develop the first commercially available mouse knob-into-hole (KIH) bispecific antibody reagents.

We launch our updated Prometheus™ antibody humanization service focused on antibody manufacturability.

2020
We launch our VivopureX™ species-matched antibodies for improved *in vivo* research.

We introduce our FleXpress™ high-throughput recombinant antibody production service.

We win a Queen's Award for Enterprise in International Trade.

We hit 10,000 antibody production runs, 3,000 hybridomas sequenced and 500 grams of antibody manufactured.

We support worldwide coronavirus R&D through new engineered reagents and transient antibody production.

We are acquired by the Seattle-based reagent company LSBio.